A 2025 52-week randomized trial in adults with heterozygous familial hypercholesterolemia (HeFH) found that daily oral Enlicitide 20 mg reduced low-density lipoprotein (LDL) cholesterol by an average of 58% at 24 weeks and maintained about a 55% reduction at 52 weeks versus placebo.
November 21, 2025
high
temporal
Global randomized clinical trial of Enlicitide in adults with genetically elevated LDL cholesterol already on lipid-lowering therapy.
A 2025 trial of Enlicitide reported additional lipid improvements: non-high-density lipoprotein (non-HDL) cholesterol decreased by 52%, apolipoprotein B decreased by 48%, and lipoprotein(a) decreased by nearly 25% in the treatment group.
November 21, 2025
high
temporal
Secondary lipid endpoint changes observed in the same 52-week Enlicitide clinical trial.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapies are typically administered by injection every few weeks, while Enlicitide was administered orally as a once-daily 20 mg pill in the 2025 trial.
November 21, 2025
high
comparative
Modes of administration for lipid-lowering therapies compared to the oral dosing regimen used for Enlicitide in the trial.
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic condition that elevates low-density lipoprotein (LDL) cholesterol and increases the risk of early-onset heart disease.
high
definition
Clinical definition and cardiovascular risk associated with HeFH
Heterozygous familial hypercholesterolemia (HeFH) has an estimated prevalence of about one in 250 people worldwide.
high
statistical
Global prevalence estimate for HeFH
PCSK9-blocking drugs (PCSK9 inhibitors) are typically administered by subcutaneous injection given every few weeks.
high
procedural
Typical delivery method and dosing interval for currently available PCSK9 inhibitor therapies
PCSK9-targeting lipid-lowering therapies and similar agents can produce reductions in low-density lipoprotein (LDL) cholesterol on the order of approximately 50â60% in treated patients.
high
statistical
Typical magnitude of LDL cholesterol reduction achievable with PCSK9-targeting therapies
Heterozygous familial hypercholesterolemia (HeFH) has an estimated global prevalence of about 1 in 250 people.
high
statistical
Prevalence estimate for the genetic disorder that elevates LDL cholesterol and increases early cardiovascular risk.